Literature DB >> 24759716

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.

James E Ross1, Nicole E Scangarella-Oman2, Robert K Flamm3, Ronald N Jones4.   

Abstract

GSK2140944 is a novel bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and methicillin-resistant Staphylococcus aureus. This quality control study was performed to establish ranges for selected control strains: S. aureus ATCC 29213 and ATCC 25923, Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247, and Streptococcus pneumoniae ATCC 49619. The control ranges will be crucial for the accurate evaluation of GSK2140944 potency as it progresses through clinical trial development.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24759716      PMCID： PMC4097705          DOI： 10.1128/JCM.00656-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  2 in total

1.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

2.  Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing.

Authors:  John Turnidge; Gerry Bordash
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191
  2 in total
  10 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.

Authors:  Ronald N Jones; Kelley A Fedler; Nicole E Scangarella-Oman; James E Ross; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 3.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

Review 4.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

5.  In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Authors:  D J Biedenbach; S K Bouchillon; M Hackel; L A Miller; N E Scangarella-Oman; C Jakielaszek; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

6.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

Review 7.  Investigational drugs to treat methicillin-resistant Staphylococcus aureus.

Authors:  Cuong Vuong; Anthony J Yeh; Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Investig Drugs       Date:  2015-11-04       Impact factor: 6.206

8.  Pharmacokinetics of Gepotidacin in Renal Impairment.

Authors:  Mohammad Hossain; Courtney Tiffany; Aparna Raychaudhuri; Dung Nguyen; Guoying Tai; Harry Alcorn; Richard A Preston; Thomas Marbury; Etienne Dumont
Journal:  Clin Pharmacol Drug Dev       Date:  2020-05-19

9.  Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment.

Authors:  Mohammad Hossain; Courtney Tiffany; Yu Tao; Aline Barth; Thomas C Marbury; Richard A Preston; Etienne Dumont
Journal:  Clin Pharmacol Drug Dev       Date:  2021-01-15

10.  Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Authors:  Pan F Chan; Velupillai Srikannathasan; Jianzhong Huang; Haifeng Cui; Andrew P Fosberry; Minghua Gu; Michael M Hann; Martin Hibbs; Paul Homes; Karen Ingraham; Jason Pizzollo; Carol Shen; Anthony J Shillings; Claus E Spitzfaden; Robert Tanner; Andrew J Theobald; Robert A Stavenger; Benjamin D Bax; Michael N Gwynn
Journal:  Nat Commun       Date:  2015-12-07       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.